| Mr Glenn Peter Stewart, OT | |
|
4-74 48th Ave, Apt 19l, Long Island City, NY 11109-5615 | |
| (646) 662-9184 | |
| Not Available |
| Full Name | Mr Glenn Peter Stewart |
|---|---|
| Gender | Male |
| Speciality | Occupational Therapist |
| Location | 4-74 48th Ave, Long Island City, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255068565 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 007248 (New York) | Primary |
| Provider Name | Score Rehabilitation Physical And Occupational Therapy Services Pllc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1336448505 PECOS PAC ID: 1456537182 Enrollment ID: O20110516000003 |
News Archive
Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced top-line data from its Phase 3 CONVERT study.
From reviewing the latest trends and clinical research in the field of endocrinology to debating the nation's obesity epidemic and the ethnic disparities in health care, the American Association of Clinical Endocrinologists' (AACE) Thirteenth Annual Meeting and Clinical Congress will highlight the current revolution in endocrinology.
The Wall Street Journal reports on the impact the health law could have on restaurants and retailers, while other news outlets explore reverberations of the Supreme Court decision making the expansion of Medicaid effectively optional.
Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best and at times contradictory. A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.
Shire plc, the global specialty biopharmaceutical company, today announced new findings on once-daily INTUNIV (guanfacine) Extended Release Tablets, the first selective alpha-2A agonist approved for the treatment of Attention Deficit Hyperactivity Disorder, at a major psychiatric meeting.
› Verified 1 days ago
| Provider Name | Metro Physical Occupational And Speech Therapy Pllc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1356742365 PECOS PAC ID: 1254553639 Enrollment ID: O20141120000039 |
News Archive
Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced top-line data from its Phase 3 CONVERT study.
From reviewing the latest trends and clinical research in the field of endocrinology to debating the nation's obesity epidemic and the ethnic disparities in health care, the American Association of Clinical Endocrinologists' (AACE) Thirteenth Annual Meeting and Clinical Congress will highlight the current revolution in endocrinology.
The Wall Street Journal reports on the impact the health law could have on restaurants and retailers, while other news outlets explore reverberations of the Supreme Court decision making the expansion of Medicaid effectively optional.
Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best and at times contradictory. A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.
Shire plc, the global specialty biopharmaceutical company, today announced new findings on once-daily INTUNIV (guanfacine) Extended Release Tablets, the first selective alpha-2A agonist approved for the treatment of Attention Deficit Hyperactivity Disorder, at a major psychiatric meeting.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Glenn Peter Stewart, OT 4-74 48th Ave, Apt 19l, Long Island City, NY 11109-5615 Ph: (646) 662-9184 | Mr Glenn Peter Stewart, OT 4-74 48th Ave, Apt 19l, Long Island City, NY 11109-5615 Ph: (646) 662-9184 |
News Archive
Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced top-line data from its Phase 3 CONVERT study.
From reviewing the latest trends and clinical research in the field of endocrinology to debating the nation's obesity epidemic and the ethnic disparities in health care, the American Association of Clinical Endocrinologists' (AACE) Thirteenth Annual Meeting and Clinical Congress will highlight the current revolution in endocrinology.
The Wall Street Journal reports on the impact the health law could have on restaurants and retailers, while other news outlets explore reverberations of the Supreme Court decision making the expansion of Medicaid effectively optional.
Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best and at times contradictory. A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.
Shire plc, the global specialty biopharmaceutical company, today announced new findings on once-daily INTUNIV (guanfacine) Extended Release Tablets, the first selective alpha-2A agonist approved for the treatment of Attention Deficit Hyperactivity Disorder, at a major psychiatric meeting.
› Verified 1 days ago
Mr. Wai Hung Steve Chan, MA OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1024 49th Ave, Long Island City, NY 11101 Phone: 917-478-0488 | |
Lindsay Erin Katzman, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2811 Queens Plz N Rm 508, Long Island City, NY 11101 Phone: 718-391-8391 | |
Ruth Santana, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3421 Crescent St, Long Island City, NY 11106 Phone: 718-392-2607 | |
Connie Sehee Jung, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2703 42nd Rd Apt 17b, Long Island City, NY 11101 Phone: 714-515-2378 | |
Moataz Abdelnabi, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 4312 Hunter St, Long Island City, NY 11101 Phone: 646-222-9350 | |
Ms. Jocelyn Librojo, OT Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 3138 34th St, Apt#2r, Long Island City, NY 11106 Phone: 718-204-4910 Fax: 212-238-7009 | |
Sherille Peggy, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2811 Queens Plz N, Long Island City, NY 11101 Phone: 917-286-5147 |